Literature DB >> 27739031

Effects and mechanisms of action of SARI on androgen-independent prostate cancer (DU145) cells.

Qian Chen1, Yonghong Gu2, Shengwang Zhang3, Hao Deng4.   

Abstract

This study aimed to characterize the role and mechanisms of action of suppressor of AP-1, regulated by IFN (SARI) in androgen-independent prostate cancer cells using the DU145 cell line. Prostate cancer cell lines were transfected to permit both the overexpression and inhibition of SARI. MTT assays and Transwell assays were performed to detect the effects of SARI overexpression and inhibition on the proliferation activity, invasiveness, and metastatic ability of DU145 cells. Expression of vascular endothelial growth factor (VEGF) and tyrosine-phosphorylated signal transducer and activator of transcription 3 (p-STAT3) was monitored in the experimental groups using a qPCR assay and western blot analysis. Additionally, DU145 cells were separately treated with 5, 50, and 100 μmol/L AG490 for 48 h and SARI expression was detected using the qPCR assay and western blot analysis. We also monitored the effects of AG490 treatment (100 μmol/L for 48 h) on both the SARI-SiRNA DU145 cells and empty vector DU145 (DU145-V) cells using the MTT assay and a Transwell migration assay. SARI overexpression and SARI-SiRNA DU145 prostate cancer cell lines were successfully established. The proliferation activity and the invasion and migration abilities of DU145-SARI cells were significantly lower compared with the DU145-V group (P < 0.05). Conversely, the proliferation activity and the invasion and migration abilities of SARI-SiRNA cells were significantly higher compared with the DU145-V group (P < 0.05). VEGF and p-STAT3 expression levels were lower in the SARI overexpression group compared with the DU145-V group and the control group (P < 0.05). In contrast, VEGF and p-STAT3 expression levels were higher in the SARI-SiRNA group compared with both the DU145-V group and the control group (P < 0.05). In comparison with the control group, SARI expression levels were higher in DU145 cells treated with 50 and 100 μmol/L AG490. Upon treatment with 100 μmol/L AG490 for 48 h, the proliferation activity and invasiveness and migration abilities of SARI-SiRNA cells were significantly higher compared with the DU145-V group (P < 0.05). SARI significantly affects the proliferation, invasion, and metastasis of DU145 cells. It is possible that SARI inhibits the proliferation, invasion, and migration of androgen-independent prostate cancer cells by regulating downstream genes through the SARI/STAT3/VEGF pathways.

Entities:  

Keywords:  AG490; P-STAT3; Prostate cancer; Sari; VEGF

Year:  2016        PMID: 27739031     DOI: 10.1007/s13277-016-5469-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma.

Authors:  Haiqing Ma; Xiaoting Liang; Yibing Chen; Ke Pan; Jiancong Sun; Hui Wang; Qijing Wang; Yongqiang Li; Jingjing Zhao; Jianjun Li; Minshan Chen; Jianchuan Xia
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 2.  Targeting the JAK2/STAT3 axis in Alzheimer's disease.

Authors:  Tomohiro Chiba; Marina Yamada; Sadakazu Aiso
Journal:  Expert Opin Ther Targets       Date:  2009-10       Impact factor: 6.902

3.  Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma.

Authors:  Haojie Wen; Yajun Chen; Zedong Hu; Qiao Mo; Jinyong Tang; Chuanzheng Sun
Journal:  Oncol Rep       Date:  2013-11-20       Impact factor: 3.906

4.  JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.

Authors:  Mei Zhao; Feng-Hou Gao; Jiong-Yi Wang; Feng Liu; Hai-Hua Yuan; Wen-Ying Zhang; Bin Jiang
Journal:  Lung Cancer       Date:  2011-02-17       Impact factor: 5.705

5.  Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN).

Authors:  Zao-zhong Su; Seok-Geun Lee; Luni Emdad; Irina V Lebdeva; Pankaj Gupta; Kristoffer Valerie; Devanand Sarkar; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

6.  Carcinogenic metalloid arsenic induces expression of mdig oncogene through JNK and STAT3 activation.

Authors:  Jiaying Sun; Miaomiao Yu; Yongju Lu; Chitra Thakur; Bailing Chen; Ping Qiu; Hongwen Zhao; Fei Chen
Journal:  Cancer Lett       Date:  2014-01-14       Impact factor: 8.679

7.  STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells.

Authors:  Zheng Wei; Xian Jiang; Haiquan Qiao; Bo Zhai; Lianfeng Zhang; Qiang Zhang; Yuanhong Wu; Hongchi Jiang; Xueying Sun
Journal:  Cell Signal       Date:  2013-01-17       Impact factor: 4.315

8.  Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis.

Authors:  Keith Syson Chan; Steve Carbajal; Kaoru Kiguchi; John Clifford; Shigetoshi Sano; John DiGiovanni
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

9.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Authors:  Daoyan Wei; Xiangdong Le; Leizhen Zheng; Liwei Wang; Jennifer A Frey; Allen C Gao; Zhihai Peng; Suyun Huang; Henry Q Xiong; James L Abbruzzese; Keping Xie
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

10.  The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis.

Authors:  Changli Wang; Yanjun Su; Lianmin Zhang; Meng Wang; Jian You; Xiaoliang Zhao; Zhenfa Zhang; Jun Liu; Xishan Hao
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.